Accelerate to discover

Back to filter

Related topics

Top 10 Pharma companies have chosen CYTEK for their flow cytometry facility

Cytek Biosciences

Jun 21, 2021

6 of Top 10 Pharma Companies (Based on total group revenues) have chosen CYTEK - full spectrum flow cytometer for their...

Jun 21, 2021

Elevated NSD3 histone methylation activity drives squamous cell lung cancer

Spectral Instruments Imaging

Jun 8, 2021

This work identifies NSD3 as a principal 8p11-12 amplicon-associated oncogenic driver in LUSC, and suggests that...

IncuCyte webinar recording: How to measure Immune Cell Killing of Tumor Cells effectively

Sartorius

Jun 4, 2021

Immuno-oncology (IO) has transformed cancer treatment. The number of treatments in the IO pipeline continues to...

White Paper: Immunophenotyping Rare Immune Cells with Laminar Wash AUTO System

Curiox

Jun 3, 2021

The Laminar Wash (LW) AUTO system consists of a wall-less plate and a laminar flow cell washer that enable automated...

Jun 21, 2021

A subset of cytotoxic effector memory T cells enhances CAR T cell efficacy in a model of pancreatic

Tonbo Biosciences

Jun 3, 2021

Tonbo Biosciences flow cytometry reagents & antibodies are manufactured with the highest quality and precision and...

Show all topics (10)

Loss of Notch1 activity inhibits prostate cancer growth

Apr 1, 2020

This study identifies Notch1 as a therapeutic target in prostate cancer. Loss of NOTCH1 in aggressive prostate cancer cells decreases proliferation, invasion, and tumorsphere formation. Therapeutic inhibition of Notch1 activity with gamma secretase inhibitors RO4929097 or DAPT in prostate cancer cells further results in decreased proliferative abilities. Loss of NOTCH1 and treatment of immunocompromised mice bearing prostate cancer xenografts with RO4929097 display significantly impaired tumor growth. Loss of NOTCH1 additionally decreased metastatic potential of prostate cancer cells in invasion assays in vitro as well as in vivo experiments. Moreover, treatment with gamma secretase inhibitors or NOTCH1 gene deletion synergized with antiandrogen therapies, enzalutamide or abiraterone, to decrease the growth of prostate cancer cells. Combination of gamma secretase inhibitors with abiraterone significantly inhibited cell migration and invasion, while combination with enzalutamide reversed enzalutamide-induced migration and invasion. These collective findings suggest loss of NOTCH1 delays growth of CRPC and inhibits metastasis, and inhibition of Notch1 activation in conjunction with second-generation antiandrogen therapies could delay growth and progression of prostate cancer.

Do you want to learn more? Read the whole article!

Scientific paper
Application

Get more info

Miroslav Vecheta

Support specialist

Miroslav

Vecheta

+420 255 700 886

Send Message

Brand profile

Spectral Instruments Imaging

Spectral Instruments Imaging manufactures instruments for preclinical optical (bioluminescent, fluorescent) and X-ray imaging.

Related products

System for individual researchers and smaller specialist teams to conduct optical imaging studies in disease model progression, response to therapy, and cell migration in-vivo.

show detail

The Ami HT and Ami HTX (includes X-Ray imaging) optical imaging systems establish a new, high throughput benchmark for in vivo imaging suitable for specialist researchers and small teams.

show detail

The Lago and X‐Ray capable Lago X optical imaging systems provide a powerful and flexible in-vivo imaging capability suitable for imaging cores, specialist researchers and small teams, delivering an unmatched 10 mouse capacity across BLI, FLI and X‐Ray.

show detail

We supply and support Life-Science Technologies in the territory of Central and Eastern Europe.

Czech Republic

Slovakia

Hungary

Poland

Croatia

Slovenia

Serbia

Romania

Bulgaria

Latvia

Lithuania

Estonia

Russia

Ukraine

Belarus

Turkey